Effectiveness of Alteplase in Management of Prosthetic Valve Thrombosis in High Risk Surgical Cases
DOI:
https://doi.org/10.51253/pafmj.v75iSUPPL-3.12771Keywords:
Alteplase, Fibrinolytic Therapy, Mechanical Heart Valve, Prosthetic Valve Thrombosis, ThrombolysisAbstract
Objective: To determine the effectiveness of alteplase in patients presented with prosthetic valve thrombosis
Study Design: Analytical Cross-Sectional study
Place and Duration of Study: Armed Forces Institute of Cardiology/National Institute of Heart Diseases, Rawalpindi Pakistan from Jan-Sep 2024.
Methodology: Patients aged 18-75years regardless of gender with left-sided mechanical prosthetic valve thrombosis who were deemed high-risk or unfit for surgery were included. Diagnosis was confirmed using transthoracic echocardiography and fluoroscopy. Patients received an accelerated dose of 50mg Alteplase intravenously over 2-hours. Follow-up evaluation included 2D-echocardiography and fluoroscopy 4-hours post-treatment to assess valve function and mobility.
Results: Twenty-two patients [males: 11(50.0%), females:11(50.0%)], with mean age 36.73±14.58years were included in the study. All patients were in NYHA class III-IV and hemodynamically unstable. Fourteen (63.6%) patients experienced Atrial Fibrillation, and 11(50.0%) had suboptimal INR, on admission. Cine-fluoroscopy revealed completely stuck valve in 15(68.2%) patients and mitral valve involved in 17(77.3%) patients. Alteplase showed complete and partial response in 14(63.6%) and 4(18.2%) patients respectively, with overall clinical improvement in 18(81.8%) patients. Patients under 40 years and males showed higher response rate (64.3%) to treatment (p>0.05). Minor bleeding occurred in 3(13.6%) patients, while no major bleeding, stroke, or hematoma was reported.
Conclusion: Alteplase, administered as an accelerated dose of 50mg over 2-hours, is an effective and safe treatment for obstructive prosthetic valve thrombosis in patients at high risk for surgery. With a high rate of clinical improvement and minimal complications, this regimen presents a viable first-line treatment for PVT.
Downloads
References
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(23): e521-643.
https://doi.org/10.1161/CIR.0000000000000031
Parashar N, Sinha M, Krishnan S, Ramakrishnan S, Seth S. Outcomes Of Thrombolysis With Tissue Plasminogen Activator In Prosthetic Heart Valve Thrombosis Patients. J Am Coll Cardiol. 2020; 75(11): 2192.
https://doi/full/10.1016/S0735-1097%2820%2932819-9
Mustafa A, Thomas T, Murdock R, Congello S. Modified fibrinolytic therapy as treatment of mechanical aortic valve thrombosis. SAGE Open Medical Case Reports. 2021; 9. https://doi.org/10.1177/2050313X21999202
Yan D, Brescia AA, Caceres J, Farhat L, Yang B. Management of Ruptured Left Ventricular Outflow Tract. Ann Thorac Surg. 2020; 109(1): e21–24.
http://dx.doi.org/10.1016/j.athoracsur.2019.04.101
Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020; 42(6).
http://dx.doi.org/10.1093/eurheartj/ehaa554
He M, Lin H, Liao Y. Response by He et al to Letter Regarding Article, “Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779.” Circulation. 2021; 144(16).
https://doi.org/10.1161/CIRCULATIONAHA.121.056310
Özkan M, Gündüz S, Gürsoy OM, Karakoyun S, Astarcıoğlu MA, Kalçık M, et al. Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Am Heart J. 2015; 170(2): 409–418. https://doi.org/10.1016/j.ahj.2015.04.025
Özkan M, Gündüz S, Güner A, Kalçık M, Gürsoy MO, Uygur B, et al. Thrombolysis or Surgery in Patients With Obstructive Mechanical Valve Thrombosis. J Am Coll Cardiol. 2022; 79(10): 977–989. http://dx.doi.org/10.1016/j.jacc.2021.12.027
Impact of Alteplase Administration Time on Clinical Outcomes in Acute Ischemic Stroke Patients - ProQuest [Internet]. Available from:
Kislitsina ON, Cox JL, Shah SJ, S. Chris Malaisrie, Kruse J, Liu M, et al. Preoperative left atrial strain abnormalities are associated with the development of postoperative atrial fibrillation following isolated coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2022; 164(3): 917–924.
https://doi.org/10.1016/j.jtcvs.2020.09.130
Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol. 2016; 68(24): 2670–2689. https://doi.org/10.1016/j.jacc.2016.09.958
Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007; 93(1): 137–142. http://dx.doi.org/10.1136/hrt.2005.071183
Khattak TH, Naqqash T, Khan MA, Kamran J, Siddiqa A, Javaid R, et al. Thrombolytic therapy in prosthetic valve thrombosis; efficacy and outcome. Pak Armed Forces Med J. 2018; 68(1): 59-63. https://www.pafmj.org/PAFMJ/article/view/3268
Morato F, Roberto M, Alyne Mendonça, Luiz A, Fidel Manuel Caceres-Loriga. Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta‐analysis. J Thromb Haemost. 2014; 12(8): 1218–1228.
https://doi.org/10.1111/jth.12577
Mahindru S, Pande S, Malhotra P, Thukral A, Kotwal AS, Gupta RP, et al. Mechanical prosthetic valve thrombosis in current era: 5-year follow-up. Indian J Thorac Cardiovasc Surg. 2020; 37(2): 140–146. https://doi.org/10.1007/s12055-020-01041-9
Sadeghipour P, Saedi S, Saneei L, Rafiee F, Yoosefi S, Parsaee M, et al. Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial. Eur Heart J- Cardiovasc Pharmacother. 2021; 8(7): 668–676.
http://dx.doi.org/10.1093/ehjcvp/pvab083
Osmonov D, Saitkulova A, Yuldashev G, Nazarov A, Tashmamatov A. The first reported case of embolic protection device implantation in a patient with prosthetic valve thrombosis treated with thrombolytic therapy: a case report. Eur Heart J - Case Rep. 2023; 7(5).
https://doi.org/10.1093/ehjcr/ytad191
Gündüz S, Kalçık M, Gürsoy MO, Güner A, Özkan M. Diagnosis, treatment & management of prosthetic valve thrombosis: the key considerations. Expert Rev Med Devices. 2020; 17(3): 209–221.
http://dx.doi.org/10.1080/17434440.2020.1733972
Dokollari A, Bisleri G, Patel D, Kalra D, Gelsomino S, Bonacchi M. The jungle of risk scores and their inability to predict long‐term survival. The truth behind the mirror. J Cardiac Surg. 2021; 36(8): 3004–3005.
Downloads
Published
License
Copyright (c) 2025 Muhammad Waleed Ghous, Asif Nadeem, Syed Akmal Shah, Ali Abbas, Muhammad Babar Khan, Muhammad Ateeq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
